Log in to save to my catalogue

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_455615

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

An interim analysis of a randomized trial in triple-negative breast cancer comparing the addition of pembrolizumab to neoadjuvant chemotherapy with chemotherapy alone and adjuvant pembrolizumab with placebo after definitive surgery was reported after 39 months of follow-up. Event-free survival at 3 years was 84.5% in the pembrolizumab group and 76....

Alternative Titles

Full title

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_swepub_ki_se_455615

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_455615

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2112651